Joanna C Badger, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 11
- 3 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
11 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Badger’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
11 of 11 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$82,028
Medicare paid this office $82,028 for 604 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 489 | $40,921 | $51 |
| Return visit (30+ min) | 103 | $10,352 | $80 |
| New patient visit (60+ min) | 58 | $8,750 | $151 |
| Destruction of precancer skin growth, 1 growth | 101 | $5,465 | $41 |
| New patient visit (45+ min) | 22 | $2,556 | $116 |
See all 13 services
| Short return visit (20+ min) | 489 | $40,921 | $51 |
| Return visit (30+ min) | 103 | $10,352 | $80 |
| New patient visit (60+ min) | 58 | $8,750 | $151 |
| Destruction of precancer skin growth, 1 growth | 101 | $5,465 | $41 |
| New patient visit (45+ min) | 22 | $2,556 | $116 |
| Long return visit (40+ min) | 18 | $2,196 | $122 |
| Biopsy of related skin growth, first growth | 61 | $1,703 | $24 |
| Short return visit | 20 | $1,082 | $32 |
| Destruction of skin growth, 1-14 growths | 15 | $1,036 | $58 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 54 | $801 | $15 |
| Destruction of precancer skin growth, 2-14 growths | 80 | $718 | $2 |
| Punch biopsy, first skin growth | 13 | $460 | $35 |
| Biopsy of related skin growth, each additional growth | 12 | $327 | $19 |
Procedures Medicare counted
| Removal of skin lesions | 141 | More than 77% of doctors who do this |
| Skin biopsy | 43 | More than 68% of doctors who do this |
Who their Medicare patients are
604 Original Medicare patients in 2024. Average age 75 · Under 65 3% · 85 and older 11% · Women 80% · Also on Medicaid 7% · Health risk score 0.94. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 54% · Coronary heart disease 18% · Diabetes 17% · Cancer 17% · Depression 17% · Atrial fibrillation 13% · Chronic kidney disease 12% · Heart failure 8% · COPD 8% · Stroke 4% · Dementia 2%.
The office billed $267,803, Medicare allowed $117,157 and paid $82,028; for 1,888 services of 27 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 604 | 1,888 | 75 | 0.94 | $267,803 | $82,028 |
| 2023 | 564 | 2,006 | 75 | 1.03 | $246,835 | $81,257 |
| 2022 | 508 | 2,011 | 76 | 1.00 | $225,064 | $73,043 |
| 2021 | 478 | 1,721 | 75 | 0.96 | $209,149 | $65,243 |
| 2020 | 447 | 1,497 | 74 | 1.12 | $183,539 | $49,488 |
| 2019 | 502 | 1,949 | 75 | 0.95 | $172,686 | $56,198 |
| 2018 | 574 | 2,120 | 74 | 1.05 | $174,525 | $64,146 |
| 2017 | 522 | 2,066 | 73 | 1.08 | $198,052 | $57,339 |
| 2016 | 525 | 2,473 | 73 | 1.03 | $267,483 | $74,989 |
| 2015 | 474 | 2,224 | 74 | 1.03 | $238,088 | $62,394 |
| 2014 | 472 | 2,055 | 73 | 1.01 | $235,328 | $62,948 |
| 2013 | 406 | 1,723 | 73 | 1.08 | $195,363 | $50,775 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Short return visit (20+ min) | 445 | $39,430 | $54 |
| Return visit (30+ min) | 153 | $13,836 | $76 |
| Destruction of precancer skin growth, 1 growth | 123 | $7,669 | $45 |
| New patient visit (45+ min) | 47 | $5,406 | $115 |
| New patient visit (60+ min) | 26 | $3,963 | $152 |
| Biopsy of related skin growth, first growth | 72 | $2,148 | $25 |
| Destruction of skin growth, 1-14 growths | 18 | $1,146 | $60 |
| Destruction of precancer skin growth, 2-14 growths | 96 | $1,099 | $2 |
| Biopsy of related skin growth, each additional growth | 23 | $716 | $20 |
| Short return visit | 17 | $456 | $27 |
2022: 10 services
| Short return visit (20+ min) | 329 | $25,394 | $49 |
| Return visit (30+ min) | 177 | $20,490 | $82 |
| Destruction of precancer skin growth, 1 growth | 120 | $7,644 | $43 |
| New patient visit (60+ min) | 33 | $5,364 | $163 |
| New patient visit (45+ min) | 46 | $4,877 | $106 |
| Long return visit (40+ min) | 16 | $1,938 | $121 |
| Biopsy of related skin growth, first growth | 72 | $1,830 | $21 |
| Destruction of precancer skin growth, 2-14 growths | 99 | $1,379 | $2 |
| Biopsy of related skin growth, each additional growth | 26 | $943 | $21 |
| Destruction of skin growth, 1-14 growths | 14 | $906 | $60 |
2021: 10 services
| Short return visit (20+ min) | 336 | $27,317 | $51 |
| Return visit (30+ min) | 136 | $13,222 | $77 |
| New patient visit (60+ min) | 52 | $7,441 | $143 |
| Destruction of precancer skin growth, 1 growth | 105 | $6,048 | $40 |
| New patient visit (45+ min) | 25 | $2,631 | $105 |
| Biopsy of related skin growth, first growth | 84 | $2,297 | $22 |
| Destruction of precancer skin growth, 2-14 growths | 93 | $914 | $2 |
| Biopsy of related skin growth, each additional growth | 32 | $895 | $18 |
| Biopsy of growth of external female genitals, first growth | 11 | $535 | $49 |
| Short return visit | 15 | $360 | $24 |
2020: 10 services
| Short return visit (20+ min) | 308 | $19,587 | $40 |
| Return visit (30+ min) | 133 | $10,816 | $67 |
| Destruction of precancer skin growth, 1 growth | 100 | $5,631 | $42 |
| New patient visit (45+ min) | 43 | $4,295 | $100 |
| Biopsy of related skin growth, first growth | 52 | $1,453 | $23 |
| New patient visit (30+ min) | 12 | $828 | $69 |
| Destruction of precancer skin growth, 2-14 growths | 81 | $756 | $2 |
| Destruction of skin growth, 1-14 growths | 15 | $704 | $47 |
| Biopsy of related skin growth, each additional growth | 20 | $614 | $18 |
| Short return visit | 22 | $468 | $19 |
2019: 11 services
| Short return visit (20+ min) | 408 | $27,813 | $41 |
| Destruction of precancer skin growth, 1 growth | 130 | $8,041 | $43 |
| New patient visit (45+ min) | 60 | $6,470 | $108 |
| Return visit (30+ min) | 63 | $4,358 | $61 |
| Biopsy of related skin growth, first growth | 65 | $1,661 | $23 |
| Destruction of precancer skin growth, 2-14 growths | 105 | $1,363 | $2 |
| Destruction of skin growth, 1-14 growths | 17 | $1,112 | $65 |
| New patient visit (30+ min) | 19 | $1,023 | $54 |
| Biopsy of related skin growth, each additional growth | 25 | $800 | $21 |
| Short return visit | 24 | $457 | $18 |
| Punch biopsy, first skin growth | 11 | $319 | $29 |
2018: 12 services
| Short return visit (20+ min) | 450 | $28,875 | $39 |
| Destruction of precancer skin growth, 1 growth | 150 | $8,643 | $39 |
| Return visit (30+ min) | 81 | $6,307 | $64 |
| New patient visit (45+ min) | 51 | $5,325 | $104 |
| Biopsy of single growth of skin and/or tissue | 94 | $3,326 | $29 |
| New patient visit (30+ min) | 48 | $2,981 | $62 |
| Destruction of skin growth, 1-14 growths | 28 | $2,105 | $62 |
| Long return visit (40+ min) | 18 | $1,724 | $91 |
| Destruction of precancer skin growth, 2-14 growths | 114 | $1,180 | $2 |
| Biopsy of each additional growth of skin and/or tissue | 24 | $810 | $23 |
| Short return visit | 21 | $644 | $24 |
| Injection into skin growth, 1-7 growths | 11 | $367 | $24 |
2017: 11 services
| Short return visit (20+ min) | 429 | $27,813 | $39 |
| Destruction of precancer skin growth, 1 growth | 160 | $9,371 | $41 |
| Return visit (30+ min) | 53 | $4,052 | $65 |
| New patient visit (45+ min) | 32 | $2,943 | $92 |
| Biopsy of single growth of skin and/or tissue | 93 | $2,779 | $27 |
| New patient visit (30+ min) | 38 | $2,230 | $59 |
| Destruction of skin growth, 1-14 growths | 25 | $2,031 | $60 |
| Long return visit (40+ min) | 14 | $1,365 | $98 |
| Destruction of precancer skin growth, 2-14 growths | 131 | $1,314 | $2 |
| Short return visit | 28 | $811 | $21 |
| Biopsy of each additional growth of skin and/or tissue | 26 | $805 | $21 |
2016: 12 services
| Short return visit (20+ min) | 417 | $30,554 | $41 |
| Destruction of precancer skin growth, 1 growth | 162 | $10,523 | $43 |
| New patient visit (45+ min) | 51 | $5,553 | $109 |
| Return visit (30+ min) | 68 | $5,527 | $67 |
| Destruction of skin growth, 1-14 growths | 55 | $4,964 | $62 |
| Biopsy of single growth of skin and/or tissue | 133 | $4,792 | $31 |
| New patient visit (30+ min) | 38 | $2,269 | $60 |
| Destruction of precancer skin growth, 2-14 growths | 135 | $1,731 | $2 |
| Biopsy of each additional growth of skin and/or tissue | 43 | $1,567 | $22 |
| Long return visit (40+ min) | 12 | $1,190 | $99 |
| Short return visit | 30 | $952 | $22 |
| Injection into skin growth, 1-7 growths | 11 | $470 | $22 |
2015: 12 services
| Short return visit (20+ min) | 397 | $28,499 | $41 |
| Destruction of precancer skin growth, 1 growth | 152 | $9,266 | $42 |
| New patient visit (45+ min) | 44 | $4,687 | $107 |
| Return visit (30+ min) | 51 | $3,838 | $58 |
| Biopsy of single growth of skin and/or tissue | 108 | $3,776 | $31 |
| Destruction of skin growth, 1-14 growths | 46 | $3,478 | $61 |
| Destruction of precancer skin growth, 2-14 growths | 127 | $1,533 | $2 |
| New patient visit (30+ min) | 27 | $1,382 | $51 |
| Short return visit | 26 | $795 | $20 |
| Biopsy of each additional growth of skin and/or tissue | 25 | $725 | $22 |
| Short return visit (20+ min) | 12 | $538 | $34 |
| Injection into skin growth, 1-7 growths | 11 | $426 | $24 |
2014: 11 services
| Short return visit (20+ min) | 389 | $28,294 | $41 |
| Destruction of precancer skin growth, 1 growth | 148 | $9,337 | $42 |
| Return visit (30+ min) | 63 | $4,690 | $64 |
| New patient visit (45+ min) | 44 | $4,351 | $99 |
| Biopsy of single growth of skin and/or tissue | 106 | $3,908 | $32 |
| Destruction of skin growth, 1-14 growths | 58 | $3,818 | $59 |
| New patient visit (30+ min) | 39 | $2,500 | $64 |
| Destruction of precancer skin growth, 2-14 growths | 118 | $1,248 | $2 |
| Biopsy of each additional growth of skin and/or tissue | 29 | $1,067 | $22 |
| Biopsy of growth of external female genitals, first growth | 13 | $808 | $54 |
| Short return visit | 31 | $762 | $22 |
2013: 10 services
| Short return visit (20+ min) | 320 | $22,103 | $39 |
| Destruction of precancer skin growth, 1 growth | 122 | $7,733 | $44 |
| New patient visit (45+ min) | 38 | $3,748 | $99 |
| Destruction of skin growth, 1-14 growths | 49 | $3,259 | $51 |
| Biopsy of single growth of skin and/or tissue | 78 | $2,765 | $29 |
| Destruction of precancer skin growth, 2-14 growths | 102 | $2,134 | $4 |
| New patient visit (30+ min) | 34 | $2,038 | $60 |
| Return visit (30+ min) | 20 | $1,647 | $66 |
| Short return visit | 53 | $1,208 | $17 |
| Biopsy of each additional growth of skin and/or tissue | 12 | $402 | $22 |
Medicaid work
$1,098 in 2024
Medicaid paid $1,098 for 27 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 27 | $1,098 |
| 2024 | 27 | 1 | 14 | $1,098 |
| 2023 | 101 | 1 | 19 | $2,075 |
| 2022 | 13 | 1 | 13 | $292 |
| 2021 | 16 | 1 | 14 | $326 |
| 2019 | 69 | 1 | 26 | $1,856 |
| 2018 | 68 | 1 | 22 | $1,749 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 101 | $2,075 |
2022
| Short return visit (20+ min) | 13 | $292 |
2021
| Short return visit (20+ min) | 16 | $326 |
2019
| Short return visit (20+ min) | 69 | $1,856 |
2018
| Short return visit (20+ min) | 68 | $1,749 |
Drugs they prescribed that Part D paid
$338,411
Pharmacies billed $338,411 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,432) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
1,276 generic and 156 brand-name prescriptions · $338,411 in drug cost · 31 antibiotic prescriptions to 22 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 14 | $47,090 | $3,364 |
| Estradiol | 120 | $13,129 | $109 |
| Clobetasol Propionate | 263 | $8,599 | $33 |
| Yuvafem | 38 | $7,363 | $194 |
| Premarin | 17 | $7,296 | $429 |
See all 29 drugs
| Dupixent | 14 | $47,090 | $3,364 |
| Estradiol | 120 | $13,129 | $109 |
| Clobetasol Propionate | 263 | $8,599 | $33 |
| Yuvafem | 38 | $7,363 | $194 |
| Premarin | 17 | $7,296 | $429 |
| Betamethasone Diprop Augmented | 67 | $2,721 | $41 |
| Fluocinonide | 43 | $2,703 | $63 |
| Pimecrolimus | 12 | $2,274 | $190 |
| Desoximetasone | 32 | $2,143 | $67 |
| Tacrolimus | 14 | $1,201 | $86 |
| Triamcinolone Acetonide | 117 | $1,188 | $10 |
| Betamethasone Valerate | 42 | $1,023 | $24 |
| Gabapentin | 72 | $921 | $13 |
| Valacyclovir | 32 | $835 | $26 |
| Dexamethasone | 25 | $707 | $28 |
| Nystatin-Triamcinolone | 30 | $698 | $23 |
| Nystatin | 33 | $654 | $20 |
| Clindamycin Phosphate | 16 | $612 | $38 |
| Betamethasone Dipropionate | 16 | $575 | $36 |
| Ketoconazole | 42 | $548 | $13 |
| Hydroxychloroquine Sulfate | 18 | $525 | $29 |
| Hydroxyzine | 16 | $387 | $24 |
| Metronidazole | 13 | $310 | $24 |
| Desonide | 13 | $308 | $24 |
| Clotrimazole | 18 | $277 | $15 |
| Acyclovir | 13 | $263 | $20 |
| Hydrocortisone | 48 | $256 | $5 |
| Finasteride | 19 | $147 | $8 |
| Fluconazole | 24 | $116 | $5 |
Year by year
| 2024 | 1,432 | 406 | 0% (0) | 11% | $338,411 |
| 2023 | 1,219 | 321 | 0% (0) | 13% | $190,503 |
| 2022 | 1,019 | 285 | 0% (0) | None | $116,953 |
| 2021 | 906 | 259 | 0% (0) | None | $86,111 |
| 2020 | 891 | 227 | None | None | $155,663 |
| 2019 | 890 | 242 | 0% (0) | 15% | $197,196 |
| 2018 | 1,050 | 294 | None | 14% | $239,606 |
| 2017 | 1,111 | 311 | None | 14% | $268,785 |
| 2016 | 1,489 | 331 | None | None | $387,175 |
| 2015 | 1,380 | 270 | None | None | $287,676 |
| 2014 | 1,351 | 250 | 1% (17) | None | $214,938 |
| 2013 | 1,146 | 236 | 1% (11) | None | $105,366 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 27 drugs
| Taltz | 12 | $77,772 | $6,481 |
| Premarin | 34 | $15,810 | $465 |
| Estradiol | 102 | $14,396 | $141 |
| Yuvafem | 33 | $6,726 | $204 |
| Tacrolimus | 17 | $6,166 | $363 |
| Clobetasol Propionate | 216 | $5,568 | $26 |
| Pimecrolimus | 13 | $3,918 | $301 |
| Imvexxy | 13 | $3,062 | $236 |
| Fluocinonide | 35 | $2,814 | $80 |
| Betamethasone Valerate | 67 | $1,967 | $29 |
| Betamethasone Diprop Augmented | 18 | $1,754 | $97 |
| Desoximetasone | 21 | $1,654 | $79 |
| Betamethasone Dipropionate | 18 | $1,534 | $85 |
| Triamcinolone Acetonide | 104 | $1,019 | $10 |
| Hydroxyzine | 40 | $794 | $20 |
| Gabapentin | 49 | $722 | $15 |
| Nystatin | 48 | $702 | $15 |
| Metronidazole | 24 | $654 | $27 |
| Ketoconazole | 32 | $473 | $15 |
| Methotrexate | 13 | $345 | $27 |
| Hydroxychloroquine Sulfate | 13 | $335 | $26 |
| Nystatin-Triamcinolone | 13 | $310 | $24 |
| Hydrocortisone | 50 | $303 | $6 |
| Finasteride | 16 | $256 | $16 |
| Clotrimazole | 11 | $206 | $19 |
| Acyclovir | 16 | $167 | $10 |
| Fluconazole | 20 | $115 | $6 |
2022: 25 drugs
| Premarin | 27 | $11,729 | $434 |
| Estradiol | 80 | $10,533 | $132 |
| Clobetasol Propionate | 225 | $8,532 | $38 |
| Yuvafem | 23 | $4,885 | $212 |
| Tacrolimus | 16 | $3,566 | $223 |
| Desoximetasone | 21 | $2,365 | $113 |
| Fluorouracil | 14 | $1,255 | $90 |
| Betamethasone Valerate | 41 | $1,227 | $30 |
| Triamcinolone Acetonide | 97 | $1,061 | $11 |
| Gabapentin | 45 | $965 | $21 |
| Nystatin | 57 | $938 | $16 |
| Betamethasone Dipropionate | 11 | $897 | $82 |
| Betamethasone Diprop Augmented | 16 | $896 | $56 |
| Fluocinonide | 13 | $751 | $58 |
| Valacyclovir | 14 | $693 | $49 |
| Metronidazole | 13 | $586 | $45 |
| Dexamethasone | 17 | $537 | $32 |
| Ketoconazole | 28 | $525 | $19 |
| Nystatin-Triamcinolone | 12 | $471 | $39 |
| Clotrimazole | 16 | $401 | $25 |
| Hydroxyzine | 17 | $377 | $22 |
| Fluconazole | 17 | $325 | $19 |
| Hydrocortisone | 41 | $248 | $6 |
| Methotrexate | 13 | $209 | $16 |
| Hydroxychloroquine Sulfate | 11 | $117 | $11 |
2021: 24 drugs
| Estradiol | 83 | $14,628 | $176 |
| Premarin | 18 | $7,323 | $407 |
| Erythromycin | 14 | $5,696 | $407 |
| Clobetasol Propionate | 167 | $5,462 | $33 |
| Tacrolimus | 35 | $5,298 | $151 |
| Yuvafem | 17 | $3,401 | $200 |
| Fluocinonide | 20 | $1,705 | $85 |
| Triamcinolone Acetonide | 97 | $1,313 | $14 |
| Desoximetasone | 11 | $1,247 | $113 |
| Betamethasone Diprop Augmented | 21 | $1,224 | $58 |
| Fluorouracil | 12 | $1,102 | $92 |
| Betamethasone Valerate | 35 | $993 | $28 |
| Clindamycin Phosphate | 13 | $848 | $65 |
| Metronidazole | 14 | $721 | $51 |
| Dexamethasone | 19 | $720 | $38 |
| Ketoconazole | 35 | $671 | $19 |
| Nystatin | 28 | $505 | $18 |
| Hydroxychloroquine Sulfate | 14 | $455 | $33 |
| Hydroxyzine | 28 | $397 | $14 |
| Gabapentin | 17 | $319 | $19 |
| Clotrimazole | 11 | $309 | $28 |
| Acyclovir | 19 | $297 | $16 |
| Hydrocortisone | 39 | $249 | $6 |
| Fluconazole | 22 | $153 | $7 |
2020: 23 drugs
| Estradiol | 72 | $13,573 | $189 |
| Premarin | 23 | $9,116 | $396 |
| Clobetasol Propionate | 141 | $5,842 | $41 |
| Yuvafem | 34 | $5,693 | $167 |
| Lidocaine | 19 | $3,722 | $196 |
| Betamethasone Diprop Augmented | 30 | $2,934 | $98 |
| Fluocinonide | 18 | $2,331 | $129 |
| Hydroxychloroquine Sulfate | 24 | $2,129 | $89 |
| Dexamethasone | 23 | $1,289 | $56 |
| Nystatin-Triamcinolone | 14 | $1,266 | $90 |
| Triamcinolone Acetonide | 79 | $1,083 | $14 |
| Betamethasone Valerate | 39 | $1,031 | $26 |
| Metronidazole | 11 | $847 | $77 |
| Hydroxyzine | 31 | $825 | $27 |
| Gabapentin | 27 | $705 | $26 |
| Nystatin | 25 | $599 | $24 |
| Ketoconazole | 16 | $551 | $34 |
| Doxycycline Hyclate | 15 | $476 | $32 |
| Venlafaxine Hcl Er | 19 | $449 | $24 |
| Acyclovir | 13 | $210 | $16 |
| Methotrexate | 13 | $185 | $14 |
| Fluconazole | 20 | $175 | $9 |
| Hydrocortisone | 23 | $142 | $6 |
2019: 21 drugs
| Premarin | 27 | $12,251 | $454 |
| Estradiol | 42 | $8,711 | $207 |
| Clobetasol Propionate | 116 | $6,586 | $57 |
| Yuvafem | 20 | $3,195 | $160 |
| Fluocinonide | 26 | $2,294 | $88 |
| Desoximetasone | 12 | $2,017 | $168 |
| Betamethasone Diprop Augmented | 28 | $1,880 | $67 |
| Hydroxychloroquine Sulfate | 20 | $1,448 | $72 |
| Dexamethasone | 28 | $1,294 | $46 |
| Gabapentin | 38 | $1,281 | $34 |
| Desonide | 14 | $919 | $66 |
| Betamethasone Valerate | 30 | $824 | $27 |
| Metronidazole | 11 | $773 | $70 |
| Triamcinolone Acetonide | 82 | $742 | $9 |
| Acyclovir | 19 | $565 | $30 |
| Doxycycline Hyclate | 11 | $485 | $44 |
| Ketoconazole | 32 | $470 | $15 |
| Hydroxyzine | 32 | $450 | $14 |
| Nystatin | 26 | $384 | $15 |
| Hydrocortisone | 34 | $199 | $6 |
| Fluconazole | 13 | $98 | $8 |
2018: 25 drugs
| Clobetasol Propionate | 138 | $10,168 | $74 |
| Premarin | 25 | $9,865 | $395 |
| Estradiol | 27 | $5,886 | $218 |
| Yuvafem | 22 | $3,575 | $162 |
| Fluorouracil | 21 | $2,995 | $143 |
| Fluocinonide | 41 | $2,943 | $72 |
| Hydroxychloroquine Sulfate | 24 | $1,651 | $69 |
| Fluocinolone Acetonide | 13 | $1,466 | $113 |
| Dexamethasone | 23 | $1,217 | $53 |
| Triamcinolone Acetonide | 112 | $1,195 | $11 |
| Metronidazole | 20 | $1,170 | $58 |
| Nystatin | 67 | $1,069 | $16 |
| Desonide | 15 | $1,054 | $70 |
| Gabapentin | 28 | $1,047 | $37 |
| Doxycycline Hyclate | 14 | $987 | $71 |
| Clindamycin Phosphate | 17 | $933 | $55 |
| Betamethasone Valerate | 32 | $876 | $27 |
| Nystop | 22 | $869 | $40 |
| Ketoconazole | 41 | $797 | $19 |
| Hydroxyzine | 25 | $597 | $24 |
| Hydrocortisone | 57 | $358 | $6 |
| Acyclovir | 17 | $267 | $16 |
| Finasteride | 14 | $90 | $6 |
| Lorazepam | 14 | $86 | $6 |
| Fluconazole | 11 | $64 | $6 |
2017: 26 drugs
| Clobetasol Propionate | 181 | $38,631 | $213 |
| Yuvafem | 53 | $11,776 | $222 |
| Lyrica | 16 | $10,644 | $665 |
| Vagifem | 33 | $10,164 | $308 |
| Premarin | 24 | $8,833 | $368 |
| Estrace | 29 | $8,162 | $281 |
| Acitretin | 14 | $6,262 | $447 |
| Fluocinonide | 54 | $4,599 | $85 |
| Desonide | 40 | $4,219 | $105 |
| Fluorouracil | 21 | $2,548 | $121 |
| Hydroxychloroquine Sulfate | 24 | $2,319 | $97 |
| Estradiol | 12 | $2,180 | $182 |
| Doxepin | 19 | $1,532 | $81 |
| Triamcinolone Acetonide | 101 | $1,388 | $14 |
| Metronidazole | 16 | $1,351 | $84 |
| Ketoconazole | 46 | $1,125 | $24 |
| Gabapentin | 30 | $998 | $33 |
| Dexamethasone | 21 | $762 | $36 |
| Hydroxyzine | 36 | $665 | $18 |
| Nystatin | 47 | $655 | $14 |
| Nystop | 13 | $493 | $38 |
| Doxycycline Hyclate | 11 | $448 | $41 |
| Hydrocortisone | 36 | $319 | $9 |
| Acyclovir | 14 | $166 | $12 |
| Fluconazole | 17 | $125 | $7 |
| Finasteride | 21 | $92 | $4 |
2016: 31 drugs
| Humira | 14 | $79,899 | $5,707 |
| Clobetasol Propionate | 273 | $49,797 | $182 |
| Vagifem | 119 | $33,187 | $279 |
| Premarin | 56 | $16,780 | $300 |
| Acitretin | 14 | $10,627 | $759 |
| Estrace | 29 | $7,395 | $255 |
| Fluocinonide | 76 | $6,981 | $92 |
| Desonide | 44 | $4,710 | $107 |
| Yuvafem | 13 | $3,425 | $263 |
| Hydroxychloroquine Sulfate | 28 | $2,644 | $94 |
| Fluorouracil | 21 | $2,495 | $119 |
| Triamcinolone Acetonide | 146 | $2,373 | $16 |
| Metronidazole | 33 | $2,325 | $70 |
| Lidocaine | 12 | $1,750 | $146 |
| Nystatin-Triamcinolone | 13 | $1,470 | $113 |
| Dexamethasone | 22 | $1,186 | $54 |
| Clindamycin Phosphate | 16 | $1,085 | $68 |
| Ketoconazole | 54 | $1,057 | $20 |
| Gabapentin | 37 | $1,053 | $28 |
| Desoximetasone | 12 | $929 | $77 |
| Doxycycline Hyclate | 11 | $860 | $78 |
| Doxepin | 16 | $493 | $31 |
| Hydroxyzine | 37 | $409 | $11 |
| Nystatin | 22 | $351 | $16 |
| Hydrocortisone | 38 | $349 | $9 |
| Azathioprine | 14 | $329 | $24 |
| Clotrimazole | 17 | $327 | $19 |
| Fluconazole | 29 | $294 | $10 |
| Acyclovir | 17 | $203 | $12 |
| Cephalexin | 12 | $73 | $6 |
| Finasteride | 16 | $69 | $4 |
2015: 33 drugs
| Clobetasol Propionate | 238 | $52,626 | $221 |
| Humira | 11 | $42,761 | $3,887 |
| Vagifem | 113 | $23,813 | $211 |
| Premarin | 48 | $12,693 | $264 |
| Estrace | 37 | $8,034 | $217 |
| Desonide | 72 | $7,884 | $109 |
| Acitretin | 12 | $5,121 | $427 |
| Fluocinonide | 37 | $3,824 | $103 |
| Nystatin-Triamcinolone | 30 | $3,713 | $124 |
| Fluocinolone Acetonide | 12 | $3,671 | $306 |
| Hydroxychloroquine Sulfate | 40 | $3,661 | $92 |
| Fluocinolone Acetonide | 18 | $2,401 | $133 |
| Lidocaine | 16 | $2,224 | $139 |
| Desoximetasone | 14 | $1,951 | $139 |
| Triamcinolone Acetonide | 123 | $1,946 | $16 |
| Clindamycin Phosphate | 25 | $1,936 | $77 |
| Fluorouracil | 11 | $1,457 | $132 |
| Doxycycline Hyclate | 11 | $1,293 | $118 |
| Econazole Nitrate | 15 | $1,266 | $84 |
| Dexamethasone | 14 | $1,239 | $88 |
| Hydroxyzine | 48 | $988 | $21 |
| Metronidazole | 12 | $738 | $61 |
| Gabapentin | 18 | $508 | $28 |
| Ketoconazole | 18 | $391 | $22 |
| Doxepin | 20 | $376 | $19 |
| Mupirocin | 20 | $300 | $15 |
| Prednisone | 33 | $253 | $8 |
| Nystatin | 11 | $241 | $22 |
| Latanoprost | 17 | $216 | $13 |
| Hydrocortisone | 17 | $162 | $10 |
| Fluconazole | 20 | $162 | $8 |
| Cephalexin | 19 | $160 | $8 |
| Acyclovir | 13 | $90 | $7 |
2014: 32 drugs
| Enbrel | 11 | $25,754 | $2,341 |
| Clobetasol Propionate | 214 | $22,734 | $106 |
| Vagifem | 117 | $14,991 | $128 |
| Premarin | 47 | $11,035 | $235 |
| Desonide | 63 | $7,645 | $121 |
| Fluocinolone Acetonide | 19 | $4,969 | $262 |
| Estrace | 26 | $4,317 | $166 |
| Nystatin-Triamcinolone | 35 | $4,137 | $118 |
| Fluocinonide | 54 | $3,461 | $64 |
| Triamcinolone Acetonide | 107 | $2,625 | $25 |
| Doxycycline Hyclate | 15 | $2,291 | $153 |
| Fluocinolone Acetonide | 14 | $2,028 | $145 |
| Metronidazole | 20 | $2,008 | $100 |
| Fluorouracil | 11 | $1,841 | $167 |
| Dexamethasone | 24 | $1,348 | $56 |
| Lidocaine | 19 | $1,251 | $66 |
| Hydroxychloroquine Sulfate | 25 | $810 | $32 |
| Gabapentin | 26 | $612 | $24 |
| Hydroxyzine | 38 | $583 | $15 |
| Nystatin | 18 | $481 | $27 |
| Econazole Nitrate | 14 | $399 | $28 |
| Mupirocin | 20 | $382 | $19 |
| Ketoconazole | 29 | $376 | $13 |
| Fluconazole | 33 | $311 | $9 |
| Doxepin | 21 | $289 | $14 |
| Prednisone | 21 | $208 | $10 |
| Latanoprost | 12 | $201 | $17 |
| Cephalexin | 22 | $197 | $9 |
| Timolol Maleate | 12 | $166 | $14 |
| Hydrocortisone | 23 | $148 | $6 |
| Venlafaxine Hcl Er | 12 | $126 | $10 |
| Citalopram Hbr | 11 | $44 | $4 |
2013: 25 drugs
| Vagifem | 129 | $12,162 | $94 |
| Soriatane | 13 | $9,045 | $696 |
| Premarin | 45 | $8,370 | $186 |
| Clobetasol Propionate | 162 | $8,142 | $50 |
| Desonide | 53 | $5,168 | $98 |
| Doxycycline Hyclate | 26 | $3,489 | $134 |
| Cymbalta | 13 | $3,009 | $231 |
| Fluorouracil | 14 | $2,686 | $192 |
| Triamcinolone Acetonide | 122 | $2,468 | $20 |
| Estrace | 17 | $2,398 | $141 |
| Fluocinolone Acetonide | 15 | $2,356 | $157 |
| Dexamethasone | 29 | $2,044 | $70 |
| Fluocinonide | 39 | $1,843 | $47 |
| Lidocaine | 17 | $1,358 | $80 |
| Nystatin | 28 | $986 | $35 |
| Nystatin-Triamcinolone | 12 | $866 | $72 |
| Ketoconazole | 35 | $655 | $19 |
| Hydroxyzine | 27 | $377 | $14 |
| Gabapentin | 17 | $344 | $20 |
| Hydrocortisone | 33 | $290 | $9 |
| Econazole Nitrate | 19 | $257 | $14 |
| Fluconazole | 27 | $246 | $9 |
| Latanoprost | 11 | $217 | $20 |
| Acyclovir | 14 | $210 | $15 |
| Prednisone | 23 | $209 | $9 |
Money from drug and device companies
$14 in 2020
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Eliquis | $14 | 1 payment
|
See the published payment
| E.R. Squibb & Sons L.L.C. | Meals · 2020-10-22 | Eliquis | $14 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1881740678
- Licence
- CA A064732
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 440 Broadway St Fl B4, Redwood City, CA, 94063
- NPI first listed
- 2007-01-26
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 440 Broadway St Fl B4, Redwood City, CA, 94063 · 900 Blake Wilbur Drive, Stanford, CA, 94301